These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30303652)

  • 21. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
    Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Iwasawa T; Ogura T; Sakai F; Kanauchi T; Komagata T; Baba T; Gotoh T; Morita S; Yazawa T; Inoue T
    Eur J Radiol; 2014 Jan; 83(1):32-8. PubMed ID: 22465123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
    Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
    Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
    Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
    Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
    Suraj KP; Kumar NK; Jyothi E; Narayan KV; Biju G
    J Assoc Physicians India; 2016 May; 64(5):36-41. PubMed ID: 27735147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
    Brown KK
    Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046
    [No Abstract]   [Full Text] [Related]  

  • 29. Idiopathic pulmonary fibrosis: A guide for nurse practitioners.
    Vega-Olivo M; Criner GJ
    Nurse Pract; 2018 May; 43(5):48-54. PubMed ID: 29465476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.
    Maher TM; Lancaster LH; Jouneau S; Morrison L; Lederer DJ; Molina-Molina M; Bendstrup E; Kirchgaessler KU; Gilberg F; Axmann J; Petzinger U; Noble PW
    Ann Am Thorac Soc; 2019 Jul; 16(7):927-930. PubMed ID: 30950636
    [No Abstract]   [Full Text] [Related]  

  • 31. Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis.
    Shimomura I; Abe M; Li Y; Tsushima K; Sakao S; Tanabe N; Ikusaka M; Tatsumi K
    Intern Med; 2019 Apr; 58(7):965-968. PubMed ID: 30568123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
    King CS; Nathan SD
    Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
    [No Abstract]   [Full Text] [Related]  

  • 33. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
    Sathiyamoorthy G; Sehgal S; Ashton RW
    South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
    Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
    Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 36. No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.
    Richeldi L; Fletcher S; Adamali H; Chaudhuri N; Wiebe S; Wind S; Hohl K; Baker A; Schlenker-Herceg R; Stowasser S; Maher TM
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30442716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2.
    Guler SA; Lindell KO; Swigris J; Ryerson CJ
    Am J Respir Crit Care Med; 2021 Feb; 203(3):P7-P8. PubMed ID: 33522880
    [No Abstract]   [Full Text] [Related]  

  • 39. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
    Harari S; Caminati A; Albera C; Vancheri C; Poletti V; Pesci A; Luppi F; Saltini C; Agostini C; Bargagli E; Sebastiani A; Sanduzzi A; Giunta V; Della Porta R; Bandelli GP; Puglisi S; Tomassetti S; Biffi A; Cerri S; Mari A; Cinetto F; Tirelli F; Farinelli G; Bocchino M; Specchia C; Confalonieri M
    Respir Med; 2015 Jul; 109(7):904-13. PubMed ID: 25962649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.